Journal
ARTHRITIS RESEARCH & THERAPY
Volume 13, Issue 2, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/ar3251
Keywords
-
Categories
Funding
- Rigel pharmaceuticals, San Francisco, CA
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042269] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from a loss of tolerance to multiple self antigens, and characterized by autoantibody production and inflammatory cell infiltration in target organs, such as the kidneys and brain. T cells are critical players in SLE pathophysiology as they regulate B cell responses and also infiltrate target tissues, leading to tissue damage. Abnormal signaling events link to defective gene transcription and altered cytokine production, contributing to the aberrant phenotype of T cells in SLE. Study of signaling and gene transcription abnormalities in SLE T cells has led to the identification of novel targets for therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available